Fewer than 30% of attending oncologists reported feeling very comfortable managing patients admitted to the hospital with severe immune-related adverse events following treatment with immune checkpoint inhibitors, according to a survey presented at the ASCO-SITC Clinical Immuno-Oncology Symposium.

“This suggests there are members of the oncology community who do not feel prepared to manage these cases, which calls for additional education, innovative care models and detailed guidelines,” Kerry Lynn Reynolds, MD, instructor of medicine at Massachusetts General Hospital, told HemOnc Today.

Read more in HemOnc Today.